These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7159070)

  • 1. Cefamandole bile levels in patients with hepatobiliary disease.
    Uwaydah M; Kantarjian H; Osseiran M; Bal'a F
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1087-9. PubMed ID: 7159070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biliary levels of ceforanide.
    Kenady DE; Ram MD
    Antimicrob Agents Chemother; 1983 May; 23(5):706-9. PubMed ID: 6870219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental and clinical study of the biliary excretion of cefamandole (author's transl)].
    Brogard JM; Pinget M; Arnaud JP; Dorner M; Adloff M; Lavillaureix J
    Pathol Biol (Paris); 1981 Jan; 29(1):25-30. PubMed ID: 7010273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.
    Ratzan KR; Baker HB; Lauredo I
    Antimicrob Agents Chemother; 1978 Jun; 13(6):985-7. PubMed ID: 677864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary concentrations of cefamandole and its use in biliary tract surgery.
    Levi JU; Livingstone AS; Martinez OV; Zeppa R; Malinin T; Hutson DG; Einhorn NC
    Scand J Infect Dis Suppl; 1980; suppl 25():55-7. PubMed ID: 6782654
    [No Abstract]   [Full Text] [Related]  

  • 6. [Chemotherapy of bile duct infections. VIII. Studies on biliary excretion of cefamandole (author's transl)].
    Tanimura H; Takenaka M; Hikasa Y; Hashino H; Rai F; Kataoka S; Sato T
    Jpn J Antibiot; 1979 Oct; 32(10):1049-55. PubMed ID: 513287
    [No Abstract]   [Full Text] [Related]  

  • 7. Decreased biliary excretion of cefamandole after percutaneous biliary decompression in patients with total common bile duct obstruction.
    Levi JU; Martinez OV; Malinin TI; Zeppa R; Livingstone A; Hutson D; Calhoun P
    Antimicrob Agents Chemother; 1984 Dec; 26(6):944-6. PubMed ID: 6524908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biliary excretion and concentration of cefazolin.
    Ram MD; Watanatittan S
    Am J Gastroenterol; 1976 Dec; 66(6):540-5. PubMed ID: 1020741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetration of clindamycin phosphate into the abnormal human biliary tract.
    Brown RB; Martyak SN; Barza M; Curtis L; Weinstein L
    Ann Intern Med; 1976 Feb; 84(2):168-70. PubMed ID: 766681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excretion of cefamandole in the bile.
    Lindahl F; Kjaer TB; Thomsen VF
    Scand J Infect Dis Suppl; 1980; suppl 25():58-9. PubMed ID: 6937953
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of cefamandole in rabbits with experimentally induced renal impairment.
    Campillo JA; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
    J Antibiot (Tokyo); 1980 Mar; 33(3):322-7. PubMed ID: 7380743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefoperazone concentrations in bile and gall bladder wall after intravenous administration.
    Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E; Hirasawa S; Abe H; Watanabe Y
    Antimicrob Agents Chemother; 1980 Dec; 18(6):980-2. PubMed ID: 6453556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the biliary excretion of different cephalosporins utilizing retrograde cholangio-pancreatography (ERCP).
    Ohnhaus EE; Halter F; Lebek G
    Endoscopy; 1981 Jan; 13(1):31-2. PubMed ID: 7460866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical versus systemic cephalosporin administration in elective biliary operations.
    Freischlag J; McGrattan M; Busuttil RW
    Surgery; 1984 Oct; 96(4):686-93. PubMed ID: 6435272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biliary squalene levels in hepatobiliary disease.
    Nosaka Y; Yamanishi Y; Hirayama C
    Gastroenterol Jpn; 1985 Aug; 20(4):338-43. PubMed ID: 4054510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of p53 and ras mutations in bile of patients with hepato-biliary disease: a prospective study in more than 100 patients.
    Müller P; Ostwald C; Püschel K; Brinkmann B; Plath F; Kröger J; Barten M; Nizze H; Schareck WD; Hauenstein K; Liebe S; Löhr JM
    Eur J Clin Invest; 2001 Mar; 31(3):240-7. PubMed ID: 11264652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of the biliary excretion of some chemotherapeutic agents in patients with biliary disease].
    Basoli A; Fiocca F; Pierini N; Schietroma M; Pianese G; Sgambati P; Giovannone D; Speranza V
    Ann Ital Chir; 1989; 60(2):129-32; discussion 133. PubMed ID: 2817651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations.
    Armstrong GC; Wise R; Brown RM; Hancox J
    Antimicrob Agents Chemother; 1981 Sep; 20(3):356-8. PubMed ID: 7030200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics of cefoperazone and cefamandole.
    Srinivasan S; Francke EL; Neu HC
    Antimicrob Agents Chemother; 1981 Feb; 19(2):298-301. PubMed ID: 6214988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of ceftizoxime compared with that of cefamandole.
    Neu HC; Srinivasan S
    Antimicrob Agents Chemother; 1981 Sep; 20(3):366-9. PubMed ID: 6272631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.